Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Stereotypes, Prejudice, and Discrimination02:55

Stereotypes, Prejudice, and Discrimination

Humans are very diverse and although we share many similarities, we also have many differences. The social groups we belong to help form our identities (Tajfel, 1974). These differences may be difficult for some people to reconcile, which may lead to prejudice toward people who are different. Prejudice is a negative attitude and feeling toward an individual based solely on one’s membership in a particular social group (Allport, 1954; Brown, 2010). Prejudice is common against people who are...
RACE - Rapid Amplification of cDNA Ends02:35

RACE - Rapid Amplification of cDNA Ends

Rapid Amplification of cDNA Ends, or RACE, is one of the most effective methods to obtain a full-length cDNA from an mRNA sequence between a known internal region to the unknown sequence at the 5’ or 3’ end. The unknown region is cloned in the cDNA by a gene-specific primer that binds the known end, and a hybrid primer that attaches a predefined anchor sequence to the unknown end of the cDNA. The sequence in between is amplified by PCR with an anchor primer and a gene-specific primer.
Since the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Posttraumatic Stress Disorder and Cardiovascular Disease: State of the Science, Knowledge Gaps, and Research Opportunities.

JAMA cardiology·2021
Same author

Association Between Neighborhood-Level Poverty and Incident Atrial Fibrillation: a Retrospective Cohort Study.

Journal of general internal medicine·2021
Same author

Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The Vaccine Safety Surveillance System Is Working.

JAMA cardiology·2021
Same author

Preventable Deaths From Heart Disease and Stroke Among Racial and Ethnic Minorities in the United States.

Circulation. Cardiovascular quality and outcomes·2021
Same author

The Journey Toward Health Equity: Are We Nearing an Abyss or Ascending a Peak?

Circulation·2021
Same author

Equity and the JAMA Network.

JAMA oncology·2021
Same journal

Neural Control of Tissue Perfusion: Emerging Evidence and Beyond.

Current hypertension reports·2026
Same journal

Correction to: Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?

Current hypertension reports·2026
Same journal

Intersection of Pediatric Hypertension and Cardiovascular-Kidney-Metabolic Disease.

Current hypertension reports·2026
Same journal

Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure?

Current hypertension reports·2026
Same journal

Leveraging the Electronic Health Record to Identify and Manage Resistant Hypertension.

Current hypertension reports·2026
Same journal

Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy?

Current hypertension reports·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Race-based therapeutics.

Clyde W Yancy1

  • 13500 Gaston Avenue, Suite H-030, Dallas, TX 75246, USA. clydey@baylorhealth.edu

Current Hypertension Reports
|July 16, 2008
PubMed
Summary
This summary is machine-generated.

Race is not a valid biologic grouping in medicine. While some diseases and risk factors vary by race, race-based treatments for cardiovascular disease, especially in African Americans, have shown limited success, prompting a shift towards personalized therapies.

More Related Videos

The Sol Braiding Method for Handling Thick Hair During Transcranial Magnetic Stimulation: An Address for Potential Bias in Brain Stimulation
04:37

The Sol Braiding Method for Handling Thick Hair During Transcranial Magnetic Stimulation: An Address for Potential Bias in Brain Stimulation

Published on: August 9, 2024

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Experiment Videos

Last Updated: Jul 3, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

The Sol Braiding Method for Handling Thick Hair During Transcranial Magnetic Stimulation: An Address for Potential Bias in Brain Stimulation
04:37

The Sol Braiding Method for Handling Thick Hair During Transcranial Magnetic Stimulation: An Address for Potential Bias in Brain Stimulation

Published on: August 9, 2024

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Area of Science:

  • Integrative Medicine and Public Health
  • Cardiovascular Disease Research
  • Pharmacogenomics and Health Disparities

Background:

  • The concept of race in medicine is biologically imprecise, as individuals of the same racial group do not necessarily share identical genetic or clinical traits.
  • Despite observed variations in disease prevalence and risk factors across racial groups, race-based therapeutic strategies have yielded limited improvements in cardiovascular disease outcomes for specific populations.
  • The African American population exhibits notable adverse cardiovascular disease variances and differential drug responses, highlighting a critical area for medical research.

Purpose of the Study:

  • To critically evaluate the utility and limitations of race as a construct in medical research and clinical practice, particularly concerning cardiovascular disease.
  • To examine the effectiveness of current race-based treatment guidelines for cardiovascular conditions in African Americans.
  • To explore the potential for optimizing therapies based on physiological markers rather than race, aiming for improved patient outcomes.

Main Methods:

  • Review of existing literature and guideline statements concerning race, cardiovascular disease, and pharmacogenomics.
  • Analysis of epidemiological data and clinical trial outcomes related to cardiovascular risk factors and treatment responses in diverse populations.
  • Exploration of emerging physiological and genetic markers for disease stratification and therapeutic individualization.

Main Results:

  • Race is not a reliable proxy for physiological differences or genetic substrates, making race-based medicine inherently problematic.
  • Current race-based treatment recommendations for cardiovascular disease in African Americans, particularly for hypertension and heart failure, have shown limited efficacy in altering disease progression.
  • Significant variations in drug responsiveness and disease presentation exist within and across racial groups, underscoring the need for more precise therapeutic approaches.

Conclusions:

  • The reliance on race in medicine is scientifically flawed and clinically inadequate for optimizing cardiovascular disease treatment.
  • Future therapeutic strategies should prioritize individualized treatment plans based on objective physiological and genetic data over broad racial categorizations.
  • Advancements in understanding disease mechanisms and drug responses at a molecular level will facilitate personalized medicine, ultimately benefiting all patients regardless of race or ethnicity.